Labcorp (LH) investor relations material

Financial performance and outlook

• Achieved 6% revenue growth and 11% adjusted EPS growth in Q1, with a 30 basis point margin expansion.

• Raised full-year guidance to 5.6% revenue growth and 10% adjusted EPS growth, expecting $1.3 billion in free cash flow.

• Diagnostic segment revenue growth expected to be 5.1–5.9%, with organic growth as the main driver and a balanced contribution from volume and price/mix.

• Utilization trends are structurally higher post-COVID, driven by aging population, innovation, and consumer engagement.

• Esoteric testing now accounts for 40% of diagnostic revenue, growing 2–3 times faster than routine testing.

Strategic initiatives and business segments

• Specialty testing areas like oncology, urology, women's health, and autoimmune are key growth priorities.

• Consumer-initiated testing via MyLabcorp OnDemand and partnerships is growing at a strong double-digit rate.

• Central Laboratory Services (CLS) posted 5% organic constant currency revenue growth in Q1 and is expected to maintain mid-single-digit growth.

• Early development business divestitures are nearly complete, streamlining operations and improving profitability.

• Margin expansion in the BLS segment is expected to outpace diagnostics, aided by strategic actions and CLS growth.

Innovation, technology, and AI

• AI is being embedded across the enterprise to enhance customer experience, operational efficiency, and innovation.

• Recent launches include an AI-enabled MyLabcorp app and Test Finder for clinicians.

• AI is expected to accelerate clinical trials, enable virtual control groups, and support non-animal testing methodologies.

• Partnerships with Amazon Web Services and Datavant aim to leverage AI for large-scale data analysis in research.